<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95889">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02054156</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMIZE-IP-12</org_study_id>
    <secondary_id>1U01HL114623-01A1</secondary_id>
    <secondary_id>1U01HL114589-01A1</secondary_id>
    <nct_id>NCT02054156</nct_id>
  </id_info>
  <brief_title>OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis</brief_title>
  <acronym>OPTIMIZE</acronym>
  <official_title>OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bonnie Ramsey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the effects of treatment with tobramycin solution
      for inhalation (TIS) with and without azithromycin in people with cystic fibrosis (CF) age 6
      months to 18 years who have early isolation of Pseudomonas aeruginosa (Pa) from a
      respiratory culture. Specimens of blood and sputum or throat swabs will be taken during the
      study along with pulmonary function testing. Participants will receive initial treatment
      with TIS followed additional treatment with TIS if quarterly respiratory cultures are
      positive for Pa in addition to either azithromycin or placebo for 18 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CF) lung disease begins in the first few months of life and follows a
      course of recurrent lower airway bacterial infection and inflammation and progression of
      disease over years and decades at a variable pace. With the development of chronic lung
      infection, obstructive disease progressively worsens, ultimately leading to respiratory
      failure. Pseudomonas aeruginosa (Pa) is the most important pathogen infecting the CF lower
      airways, and its acquisition early in life is associated with a pro-inflammatory effect,
      lower lung function, poor nutritional outcomes, and decreased survival.

      Pseudomonas aeruginosa (Pa) infection of the cystic fibrosis (CF) airway typically proceeds
      from early infection to chronic infection. Although some studies have shown that a minority
      of individuals with CF spontaneously clear early Pseudomonas aeruginosa (Pa) infection, data
      from multiple studies suggest that antibiotics are superior to no treatment in clearing
      Pseudomonas aeruginosa (Pa) from respiratory cultures. Understanding the transition period
      from early to chronic Pseudomonas aeruginosa (Pa) infection is thus of critical importance
      in identifying strategies to prevent this progression.

      The study will assess the clinical and microbiologic efficacy and safety of azithromycin
      given three times weekly in combination with standardized tobramycin solution for inhalation
      (TIS) therapy among children with early Pseudomonas aeruginosa (Pa). TIS therapy is defined
      as an initial eradication treatment with 1-2 courses of 28 days TIS and subsequent 28 day
      treatments only at times a quarterly respiratory culture is positive for Pseudomonas
      aeruginosa (Pa). Eligible participants will be randomized within one month of their
      Pseudomonas aeruginosa (Pa) positive culture to receive one of the following two treatment
      strategies for 18 months: (1) oral placebo in addition to standardized TIS therapy, or (2)
      oral azithromycin in addition to standardized TIS therapy.

      At the first study visit, participants will undergo a physical examination and a review of
      their medical history. Lung function will be measured via spirometry (in children greater
      than four years of age who are able to perform spirometry), electrocardiogram (ECG) testing
      will be conducted, and hearing ability will be measured via audiometry. Blood will be drawn
      for laboratory tests and a specimen will be obtained for a respiratory culture before
      randomization and study drug dispensing occurs. Subsequent study visits will take place at
      Day 21, Weeks 13, 26, 39, 52, 65, and 78. At each visit, participants will undergo a
      physical examination, a spirometry test (as appropriate), a respiratory specimen for
      Pseudomonas aeruginosa (Pa) culture will be collected and study drug will be dispensed
      (except at Week 78). Participants will complete self-report or parent-completed respiratory
      symptom questionnaires and signs and symptoms evaluations will be performed at all visits.
      Repeat hearing and laboratory tests will be performed at Weeks 39 and 78 and ECG testing
      will be repeated at Day 21 and Week 78.  Participants will be required to maintain a
      medication diary throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to a protocol-defined pulmonary exacerbation</measure>
    <time_frame>Over the 18-month study period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Pseudomonas aeruginosa (Pa) recurrence</measure>
    <time_frame>Over the 18-month study period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by the incidence of adverse events and laboratory abnormalities</measure>
    <time_frame>Over the 18- month study period</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">274</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>azithromycin and TIS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>azithromycin and tobramycin solution for inhalation (TIS) Azithromycin 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg,  for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo and TIS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo and tobramycin solution for inhalation (TIS) Placebo 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin</intervention_name>
    <description>3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg,  for 18 months</description>
    <arm_group_label>azithromycin and TIS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months</description>
    <arm_group_label>placebo and TIS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin solution for inhalation</intervention_name>
    <description>300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months</description>
    <arm_group_label>azithromycin and TIS</arm_group_label>
    <arm_group_label>placebo and TIS</arm_group_label>
    <other_name>TIS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 6 months to ≤ 18 years

          -  Documentation of a CF diagnosis as evidenced by one or more clinical features
             consistent with the CF phenotype or positive CF Newborn Screening result for
             immunoreactive trypsinogen (IRT) IRT/DNA or IRT/IRT and one or more of the following
             criteria:

          -  sweat chloride ≥ 60 milliequivalent (mEq)/liter by quantitative by pilocarpine
             iontophoresis test (QPIT)

          -  two well-characterized mutations in the cystic fibrosis transmembrane conductive
             regulator (CFTR) gene

          -  Abnormal nasal potential difference (NPD) (change in NPD in response to a low
             chloride solution and  isoproteronol of less than - 5 mV)

          -  Documented new positive oropharyngeal, sputum or lower respiratory tract culture for
             Pa within 30 days of the Baseline Visit (Visit 1), defined as: a) first lifetime
             documented Pa   positive culture; or b) Pa recovered after at least a two-year
             history of Pa negative respiratory cultures (≥ 1 culture/ year)

          -  Clinically stable with no evidence of any significant respiratory symptoms at the
             Baseline Visit that would  require administration of intravenous anti- pseudomonal
             antibiotics, oxygen supplementation, and/or hospitalization as determined by the
             study physician

          -  Written informed consent obtained from participant or participant's legal
             representative (and assent when applicable) and ability for participant to comply
             with the requirements of the study

        Exclusion Criteria:

          -  Macrolide antibiotic use within 30 days of the Baseline Visit

          -  Initiation of current course of treatment with TIS &gt;14 days  prior to Baseline Visit

          -  Weight &lt;6.0 kg at the Baseline Visit

          -  History of aminoglycoside hypersensitivity or adverse  reaction to inhaled
             aminoglycoside

          -  History of azithromycin hypersensitivity or adverse reaction to azithromycin or
             allergy to  macrolide antibiotics

          -  History of positive respiratory culture for Non-tuberculous mycobacteria (NTM) or
             Burkholderia cepacia complex within 2 years of the Baseline Visit

          -  History of unresolved, abnormal renal function (defined as serum creatinine greater
             than 1.5 times the upper limit of normal for age).

          -  History of unresolved, abnormal liver function tests (defined as alanine
             aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater than 4 times
             the upper  limit of normal range) or history of portal hypertension

          -  History of unresolved, abnormal neutropenia (ANC ≤ 1000)

          -  Abnormal ECG test at the Baseline Visit defined as a QT interval corrected (QTc)  (B)
             of ≥460 msec or history of ventricular arrhythmia

          -  History of abnormal hearing sensitivity defined as hearing threshold levels &gt;25 dB HL
             (decibels Hearing Level) for  visual reinforcement audiometry (VRA) at any frequency
             (500-4000Hz) or &gt;20 Decibels Hearing Level (dBHL) for play or standard audiometry at
             any two frequencies (500-8000Hz) in either ear, not associated with middle ear
             disease (including infection) or a flat (Type B) tympanogram

          -  New initiation of chronic therapy (greater than 21 days)  with drugs known to prolong
             QT interval including ciprofloxacin and trimethoprim-sulfa (refer to Appendix III)
             within 30 days prior to the Baseline Visit or coadministration of nelfinavir or oral
             anticoagulants

          -  Positive serum or urine pregnancy test at the Baseline Visit (to be performed on all
             females of child-bearing potential)  or for females of child bearing potential:
             pregnant, breastfeeding, or unwilling to use barrier contraception during
             participation in the study

          -  Administration of any investigational drug within 30 days prior to the Baseline Visit

          -  Presence of a condition or abnormality (e.g., pre-existing heart disease) that in the
             opinion of the site investigator would compromise the safety of the participant or
             the quality of the data
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonnie Ramsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Center for Clinical and Translational Research, CF Therapeutics Development Network Clinical Coordinating Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole Hamblett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Core for Biomedical Statistics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Kirihara</last_name>
    <phone>206-884-7593</phone>
    <email>Jean.kirihara@seattlechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irene Bondick</last_name>
    <phone>206-884-7813</phone>
    <email>Irene.bondick@seattlechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CFF Affiliate Program Providence Medical Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99519-6604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Nelson</last_name>
      <email>Katherine.Nelson2@providence.org</email>
    </contact>
    <investigator>
      <last_name>Dion Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center Arizona Health Science Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Osmara Molina de Rodriguez</last_name>
      <email>omolina@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Cori Daines, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Ross</last_name>
      <email>ANRoss@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Gulnur Com, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Colleen Dunn</last_name>
      <email>cedunn@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Carlos Milla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meg Anthony</last_name>
      <email>Meg.Anthony@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Gwendolyn Kerby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catalina Guzman</last_name>
      <email>catalina.guzman@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Marie Egan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Nemours Children's Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth DeLuca</last_name>
      <email>bdeluca@nemours.org</email>
    </contact>
    <investigator>
      <last_name>David Schaeffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program All Children's Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy Hosler</last_name>
      <email>Kathy.Hosler@allkids.org</email>
    </contact>
    <investigator>
      <last_name>Magdalen Gondor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Affiliate Program Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petra Raville</last_name>
      <email>petra.raville@choa.org</email>
    </contact>
    <investigator>
      <last_name>Kevin Kirchner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Derrick Carter</last_name>
      <email>derrick.carter@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Arlene Stecenko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center St. Luke's CF Clinic</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dixie Durham</last_name>
      <email>durhamd@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Perry Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Matthews</last_name>
      <email>tmatthews@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Adrienne Savant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5271</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Bendy</last_name>
      <email>lbendy@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Teresi</last_name>
      <email>mary-teresi@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Ahrens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carrie Milliard</last_name>
      <email>millic@mmc.org</email>
    </contact>
    <investigator>
      <last_name>AnneMarie Cairns, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn Kruse</last_name>
      <email>dmkruse@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Samya Nasr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Van Wagnen</last_name>
      <email>cvanwag@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Ibrahim Abdulhamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rose Thompson</last_name>
      <email>rtthompson@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Philip Black, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Cardinal Glennon Children's Hospital/Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Cooper</last_name>
      <email>acoope16@slu.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Albers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Burks</last_name>
      <email>Burks_P@kids.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Albert Faro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raquel Telfer</last_name>
      <email>raquel.telfer@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Heather Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Monmouth Medical Center</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bridget Marra</last_name>
      <email>bmarra@barnabashealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Zanni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juyan Zhou</last_name>
      <email>Jz78@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Saiman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Nix</last_name>
      <email>Nancy_Nix@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Clement Ren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donna Lindner</last_name>
      <email>lindnerd@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Fortner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingrid Gherson</last_name>
      <email>ingrid_gherson@nymc.edu</email>
    </contact>
    <investigator>
      <last_name>John Welter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Moormann</last_name>
      <email>kelly.moormann@unc.edu</email>
    </contact>
    <investigator>
      <last_name>George Retsch-Bogart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miranda West</last_name>
      <email>miranda.west@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Deanna Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorrie Duan</last_name>
      <email>lorrie.duan@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>John Clancy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberta Ksenich</last_name>
      <email>Roberta.Ksenich@UHHospitals.org</email>
    </contact>
    <investigator>
      <last_name>James Chmiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Johnson</last_name>
      <email>Terri.Johnson@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Karen McCoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Oregon Health &amp; Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra Cornell</last_name>
      <email>cornell@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Kim Simmons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane Kitch</last_name>
      <email>dkitch@psu.edu</email>
    </contact>
    <investigator>
      <last_name>Gavin Graff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jamie Adams</last_name>
      <email>adamsjm2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>David Orenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Sanford USD Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn Hanson</last_name>
      <email>Dawn.Hanson@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>James Wallace,, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isolde Brazil</last_name>
      <email>IBrazil@seton.org</email>
    </contact>
    <investigator>
      <last_name>Jason Fullmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Oldroyd</last_name>
      <email>heather.oldroyd@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara Chatfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Children's Hospital of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carrie Johnson</last_name>
      <email>Carrie.Johnson@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Laura Sass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center Medical College of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Ward</last_name>
      <email>wardmt@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alan Genatossio</last_name>
      <email>alan.genatossio@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Margaret Rosenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Makholm</last_name>
      <email>Lmakholm@uwhealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Rock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Care Center &amp; Pediatric Program Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theresa Kump</last_name>
      <email>tkump@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Noe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 1, 2014</lastchanged_date>
  <firstreceived_date>February 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Bonnie Ramsey</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Cystic fibrosis (CF)</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Tobramycin solution for inhalation (TIS)</keyword>
  <keyword>Pseudomonas aeruginosa (Pa)</keyword>
  <keyword>Early Pseudomonas aeruginosa infection</keyword>
  <keyword>Pulmonary exacerbation</keyword>
  <keyword>Standardized anti-pseudomonal  therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
